


IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Claim 1 (Previously Amended).

A compound of structural formula I:



or a pharmaceutically acceptable salt or an enantiomer thereof, wherein

n is 0, 1 or 2;

$a-b$ represents $\text{CF}=\text{CH}$, CHFCH_2 , or CF_2CH_2 ;

R^1 is hydrogen, hydroxymethyl, or C_{1-3} alkyl, wherein alkyl is unsubstituted or substituted with one to seven fluorine atoms;

R^2 is hydrogen or C_{1-4} alkyl;

R^3 is selected from

$(\text{CH}_2)_n$ -cycloheteroalkyl, and

$(\text{CH}_2)_n$ -aryl, wherein aryl is selected from

- (1) phenyl,
- (2) naphthyl,
- (3) benzimidazolyl,
- (4) imidazopyridinyl,
- (5) benzofuranyl,
- (6) benzothiophenyl,
- (7) benzoxazolyl,
- (8) benzothiazolyl,
- (9) benzodihydrofuranyl,
- (10) 1,3-benzodioxolyl,
- (11) 2,3-dihydro-1,4-benzodioxinyl,
- (12) indolyl,


- (13) quinolyl,
- (14) isoquinolyl,
- (15) furanyl,
- (16) thienyl,
- (17) imidazolyl,
- (18) oxazolyl,
- (19) thiazolyl,
- (20) isoxazolyl,
- (21) isothiazolyl,
- (22) pyrazolyl,
- (23) pyrrolyl,
- (24) pyridyl,
- (25) pyrimidyl,
- (26) pyrazinyl,
- (27) thiadiazolyl,
- (28) oxadiazolyl,
- (29) triazolyl,
- (30) tetrazolyl, and
- (31) indanyl;

wherein the alkyl group or the cycloheteroalkyl group is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, and C₁₋₄ alkoxy; the aryl group as defined in items (1) to (30) is unsubstituted or substituted with one to three groups independently selected from halogen, phenyl, C₁₋₈ alkyl, C₃₋₈ cycloalkyl, C₃₋₈ cycloheteroalkyl, phenyl-C₁₋₆ alkyl, amino-C₀₋₆ alkyl, C₁₋₆ alkylamino-C₀₋₆ alkyl, (C₁₋₆ alkyl)₂amino-C₀₋₆ alkyl, phenyl-C₀₋₆ alkylamino-C₀₋₆ alkyl, (phenyl-C₀₋₆ alkyl)₂amino-C₀₋₆ alkyl, C₁₋₆ alkylthio, phenyl-C₀₋₆ alkylthio, C₁₋₆ alkylsulfinyl, phenyl-C₀₋₆ alkylsulfinyl, C₁₋₆ alkylsulfonyl, phenyl-C₀₋₆ alkylsulfonyl, C₁₋₆ alkoxy-C₀₋₆ alkyl, phenyl-C₀₋₆ alkoxy-C₀₋₆ alkyl, hydroxycarbonyl-C₀₋₆ alkyl, C₁₋₆ alkoxycarbonyl-C₀₋₆ alkyl, phenyl-C₀₋₆ alkoxycarbonyl-C₀₋₆ alkyl, hydroxycarbonyl-C₁₋₆ alkyloxy, hydroxy-C₀₋₆ alkyl, cyano, nitro, perfluoro-C₁₋₄ alkyl, perfluoro-C₁₋₄ alkoxy, oxo, C₁₋₆ alkylcarbonyloxy, phenyl-C₀₋₆ alkylcarbonyloxy, C₁₋₆ alkylcarbonylamino, phenyl-C₀₋₆ alkylcarbonylamino, C₁₋₆ alkylsulfonylamino, phenyl-C₀₋₆ alkylsulfonylamino, C₁₋₆ alkoxycarbonylamino, phenyl-C₀₋₆ alkoxycarbonylamino, C₁₋₆ alkylaminocarbonylamino, phenyl-C₀₋₆ alkylaminocarbonylamino, (C₁₋₆ alkyl)₂ aminocarbonylamino, (phenyl-C₀₋₆ alkyl)₂ aminocarbonylamino, (C₁₋₆ alkyl)₂ aminocarbonyloxy, and (phenyl-C₀₋₆ alkyl)₂

aminocarbonyloxy; and wherein any methylene (CH_2) carbon atom in $(\text{CH}_2)_n$ is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C₁₋₄ alkyl; or two substituents when on the same methylene (CH_2) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group;
or R² and R³ together form a 5- or 6-membered saturated ring fused with a 5- or 6-membered aromatic ring system having 0, 1, or 2 heteroatoms selected from the N, O, and S.

Claim 2 (Original). The compound of Claim 1 wherein R¹ is hydrogen or methyl.

Claim 3 (Presently amended). A compound of structural formula I:



or a pharmaceutically acceptable salt or an enantiomer thereof; wherein
n is 0, 1 or 2;

a-b represents CF=CH, CHFCH₂, or CF₂CH₂;

R¹ is hydrogen, hydroxymethyl, or C₁₋₃ alkyl, wherein alkyl is unsubstituted or substituted with one to seven fluorine atoms;

R² is hydrogen or C₁₋₄ alkyl;

R³ is selected from

$(\text{CH}_2)_n$ -aryl, wherein aryl is selected from

- (1) phenyl,
- (2) naphthyl,
- (3) benzimidazolyl,
- (4) imidazopyridinyl,
- (45) benzofuranyl,
- (56) benzothiophenyl,
- (67) benzoxazolyl,

- (78) benzothiazolyl,
- (89) benzodihydrofuranyl,
- (910) 1,3-benzodioxolyl,
- (1011) 2,3-dihydro-1,4-benzodioxinyl,
- (1112) indolyl,
- (1213) quinolyl,
- (1314) isoquinolyl,
- (1415) furanyl,
- (1516) thienyl,
- (1617) imidazolyl,
- (1718) oxazolyl,
- (1819) thiazolyl,
- (1920) isoxazolyl,
- (2021) isothiazolyl,
- (2122) pyrazolyl,
- (2223) pyrrolyl,
- (2324) pyridyl,
- (2425) pyrimidyl,
- (2526) pyrazinyl,
- (2627) thiadiazolyl,
- (2728) oxadiazolyl,
- (2829) triazolyl,
- (2930) tetrazolyl, and
- (3031) indanyl;

wherein the alkyl group or the cycloheteroalkyl group is unsubstituted or substituted with one to three substituents independently selected from halogen, hydroxy, and C1-4 alkoxy; the aryl group as defined in items (1) to (30) is unsubstituted or substituted with one to three groups independently selected from halogen, phenyl, C1-8 alkyl, C3-8 cycloalkyl, C3-8 cycloheteroalkyl, phenyl-C1-6 alkyl, amino-C0-6 alkyl, C1-6 alkylamino-C0-6 alkyl, (C1-6 alkyl)2amino-C0-6 alkyl, phenyl-C0-6 alkylamino-C0-6 alkyl, (phenyl-C0-6 alkyl)2amino-C0-6 alkyl, C1-6 alkylthio, phenyl-C0-6 alkylthio, C1-6 alkylsulfinyl, phenyl-C0-6 alkylsulfinyl, C1-6 alkylsulfonyl, phenyl-C0-6 alkylsulfonyl, C1-6 alkoxy-C0-6 alkyl, phenyl-C0-6 alkoxy-C0-6 alkyl, hydroxycarbonyl-C0-6 alkyl, C1-6 alkoxycarbonyl-C0-6 alkyl, phenyl-C0-6 alkoxycarbonyl-C0-6 alkyl, hydroxycarbonyl-C1-6 alkyloxy, hydroxy-C0-6 alkyl, cyano, nitro, perfluoro-

C₁₋₄ alkyl, perfluoro-C₁₋₄ alkoxy, oxo, C₁₋₆ alkylcarbonyloxy, phenyl-C₀₋₆ alkylcarbonyloxy, C₁₋₆ alkylcarbonylamino, phenyl-C₀₋₆ alkylcarbonylamino, C₁₋₆ alkylsulfonylamino, phenyl-C₀₋₆ alkylsulfonylamino, C₁₋₆ alkoxy carbonylamino, phenyl-C₀₋₆ alkoxy carbonylamino, C₁₋₆ alkylaminocarbonylamino, phenyl-C₀₋₆ alkylaminocarbonylamino, (C₁₋₆ alkyl)₂ aminocarbonylamino, (phenyl-C₀₋₆ alkyl)₂ aminocarbonylamino, (C₁₋₆ alkyl)₂ aminocarbonyloxy, and (phenyl-C₀₋₆ alkyl)₂ aminocarbonyloxy; and wherein any methylene (CH₂) carbon atom in (CH₂)_n is unsubstituted or substituted with one to two groups independently selected from halogen, hydroxy, and C₁₋₄ alkyl; or two substituents when on the same methylene (CH₂) group are taken together with the carbon atom to which they are attached to form a cyclopropyl group; or R² and R³ together form a 5- or 6-membered saturated ring fused with a 5- or 6-membered aromatic ring system having 0, 1, or 2 heteroatoms selected from the N, O, and S.

Claim 4 (Original). The compound of Claim 3, wherein R¹ is hydrogen or methyl.

Claim 5 (Original). The compound of Claim 1 wherein a-b represents CF=CH.

Claim 6 (Original). The compound of Claim 1 wherein a-b represents CHFCH₂.

Claim 7 (Original). The compound of Claim 1 wherein R² is hydrogen and R³ is (CH₂)_n-aryl.

Claim 8 (Original). The compound of Claim 7 wherein n is 0 or 1.

Claim 9 (Original). The compound of Claim 1 wherein R¹ is methyl, a-b represents CF=CH, R² is hydrogen, and R³ is (CH₂)_n-aryl.

Claim 10 (Original). The compound of Claim 9 wherein n is 0 or 1.

Claim 11 (Original). The compound of Claim 1 wherein R¹ is methyl, a-b represents CHFCH₂, R² is hydrogen, and R³ is (CH₂)_n-aryl.

Claim 12 (Original). The compound of Claim 11 wherein n is 0 or 1.

Claim 13 (Original). The compound of Claim 1 wherein R¹ is methyl, a-b represents CF=CH, R² is hydrogen, and R³ is (CH₂)_n-cycloheteroalkyl.

Claim 14 (Original). The compound of Claim 13, wherein n is 0 or 1.

Claim 15 (Original). The compound of Claim 1 wherein R¹ is methyl, a-b represents CHFCH₂, R² is hydrogen, and R³ is (CH₂)_n-cycloheteroalkyl.

Claim 16 (Original). The compound of Claim 15, wherein n is 0 or 1.

Claim 17 (Previously amended). The compound of Claim 2 chosen from:

N-(2-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(3-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2-trifluoromethylphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2-chlorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(4-methoxyphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(3-methoxyphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2-methylphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(3-methylphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2-fluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(3-fluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(4-fluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(4-chloro-2-fluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2,4-difluorophenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(α -methylphenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(phenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(4-chloro-2-trifluoromethylphenyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(5-methylpyridin-2-yl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(thiophen-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(thiophen-3-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2-trifluoromethylphenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(benzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;

N-(1-methylbenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(1-methyl-5-trifluoromethylbenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(5-chlorobenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(5-methoxybenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(benzthiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2,3-dihydro-1,4-benzodioxin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(thiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(4-methylthiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(thiazol-4-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(1-methylimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(tetrahydro-2H-pyran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(tetrahydro-2H-pyran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2,3-dihydro-1,4-benzodioxin-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2,3-dihydro-1,4-benzodioxin-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(tetrahydrofuran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(tetrahydrofuran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(3H-imidazo[4,5-*b*]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(2-fluorophenylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(2-trifluoromethylphenylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(3-methoxyphenyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(4-methoxyphenyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(2-trifluoromethylphenyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(2-chlorophenyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(2-fluorophenylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(benzimidazol-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;

N-(1-methylbenzimidazol-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(thiazol-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(furan-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide; and
N-(thiophen-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
pharmaceutically acceptable salts and enantiomers thereof.

Claim 18 (Original).

The compound of Claim 17 chosen from:

N-(2-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(3-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(5-chlorobenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(5-methoxybenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide;
N-(benzthiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(tetrahydro-2H-pyran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide;
N-(tetrahydro-2H-pyran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide;
N-(2,3-dihydro-1,4-benzodioxin-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide;
N-(2,3-dihydro-1,4-benzodioxin-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide;
N-(tetrahydrofuran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(tetrahydrofuran-2(R)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide;
N-(3H-imidazo[4,5-*b*]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide;
N-(2-fluorophenylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(thiazol-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
N-(furan-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide; and
N-(thiophen-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide;
pharmaceutically acceptable salts and enantiomers thereof.

Claim 19 (Original).

The compound of Claim 18 chosen from:

N-(tetrahydro-2H-pyran-2(S)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide;

N-(tetrahydro-2*H*-pyran-2(*R*)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(2,3-dihydro-1,4-benzodioxin-2(*R*)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(2,3-dihydro-1,4-benzodioxin-2(*S*)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(tetrahydrofuran-2(*S*)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(tetrahydrofuran-2(*R*)-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(3*H*-imidazo[4,5-*b*]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
pharmaceutically acceptable salts and enantiomers thereof.

Claim 20 (Original). The compound of Claim 18 chosen from:

N-(2-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(3-fluorophenylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(5-chlorobenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(5-methoxybenzimidazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(benzthiazol-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5*α*-androst-1-en-17*β*-carboxamide;
N-(2-fluorophenylmethyl)-2*α*-fluoro-4-methyl-3-oxo-4-aza-5*α*-androstan-17*β*-carboxamide;
N-(thiazol-2-ylmethyl)-2*α*-fluoro-4-methyl-3-oxo-4-aza-5*α*-androstan-17*β*-carboxamide;
N-(furan-2-ylmethyl)-2*α*-fluoro-4-methyl-3-oxo-4-aza-5*α*-androstan-17*β*-carboxamide; and
N-(thiophen-2-ylmethyl)-2*α*-fluoro-4-methyl-3-oxo-4-aza-5*α*-androstan-17*β*-carboxamide;
pharmaceutically acceptable salts and enantiomers thereof.

Claim 21 (Previously Canceled).

Claim 22 (Previously Canceled).

Claim 23 (Previously Canceled).

Claim 24 (Previously Canceled).

Claim 25 (Previously Canceled).

Claim 26 (Previously Canceled).

Claim 27 (Previously Canceled).

Claim 28 (Previously Canceled).

Claim 29 (Previously Canceled).

Claim 30 (Previously Canceled).

Claim 31 (Previously Canceled).

Claim 32 (Previously Canceled).

Claim 33 (Previously Canceled).

Claim 34 (Previously Canceled).

Claim 35 (Previously Canceled).

Claim 36 (Previously Canceled).

Claim 37 (Previously Canceled).

Claim 38 (Previously Canceled).

Claim 39 (Previously Canceled).

Claim 40 (Previously Canceled).

Claim 41 (Previously Canceled).

Claim 42 (Newly Presented).

A compound of Claim 18, chosen from:

N-(2,2,2-trifluoroethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide,
N-(2-fluorophenylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide,
N-(benzimidazol-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide,
N-(3*H*-imidazo[4,5-*b*]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide, pharmaceutically acceptable salts and enantiomers thereof.

Claim 43 (Newly Presented). A compound chosen from:

N-(2,2,2-trifluoroethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -carboxamide,
pharmaceutically acceptable salts and enantiomers thereof.

Claim 44 (Newly Presented). A compound chosen from:

N-(2-fluorophenylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide,
pharmaceutically acceptable salts and enantiomers thereof.

Claim 45 (Newly Presented). A compound chosen from:

N-(benzimidazol-2-ylmethyl)-2 α -fluoro-4-methyl-3-oxo-4-aza-5 α -androstan-17 β -carboxamide,
pharmaceutically acceptable salts and enantiomers thereof.


Claim 46 (Newly Presented). A compound chosen from:

N-(3*H*-imidazo[4,5-*b*]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide, pharmaceutically acceptable salts and enantiomers thereof.

Claim 47 (Newly Presented). A compound

N-(3*H*-imidazo[4,5-*b*]pyridin-2-ylmethyl)-2-fluoro-4-methyl-3-oxo-4-aza-5 α -androst-1-en-17 β -
carboxamide.

Claim 48 (Newly Presented). A compound of structural formula:



pharmaceutically acceptable salts and enantiomers thereof.

Claim 49 (Newly Presented).

A compound of structural formula:

